drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous T cells)
drug_description
Patient-derived tumor-resident T cells isolated, expanded, and activated ex vivo, then reinfused to mediate antigen-specific cytotoxicity via TCR recognition of tumor antigens.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-resident T cells are isolated from the patient’s tumor, expanded and activated ex vivo, then reinfused to recognize tumor antigens via their native TCRs presented on MHC, mediating antigen-specific cytotoxicity through perforin/granzyme release and cytokine secretion; supportive IL-2 can enhance survival and expansion.
drug_name
Autologous tumor-infiltrating lymphocyte (TIL) cells
nct_id_drug_ref
NCT06334783